ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 24, 2017 Fri, 24 Nov 2017 15:20:35 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Adamas Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ADMS-US. Comparing the performance and risk of Adamas Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Adamas to Present at Two Upcoming Investor Conferences Wed, 22 Nov 2017 17:42:07 +0000 EMERYVILLE, Calif., Nov. 22, 2017-- Adamas Pharmaceuticals, Inc. today announced that company management is scheduled to present at two upcoming investor conferences:. Richard A. King, the company’ s Chief ...
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops Tue, 21 Nov 2017 21:29:09 +0000 Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.
Adamas Announces New Employment Inducement Grant Wed, 08 Nov 2017 21:17:50 +0000 EMERYVILLE, Calif., Nov. 08, 2017-- Adamas Pharmaceuticals, Inc. today announced that the compensation committee of the company’ s board of directors granted five new employees the option to purchase an ...
Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:17:10 +0000 Categories: Yahoo FinanceGet free summary analysis Adamas Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Adamas Pharmaceuticals, Inc. – Catalyst Biosciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc Sponsored ADR and AbbVie, Inc. (CBIO-US, MRK-US, GSK-US and ABBV-US) that have also reported for ... Read more
(Read more...)
Adamas reports 3Q loss Thu, 02 Nov 2017 21:26:36 +0000 On a per-share basis, the Emeryville, California-based company said it had a loss of $1.04. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results Thu, 02 Nov 2017 20:01:00 +0000 EMERYVILLE, Calif., Nov. 02, 2017-- Adamas Pharmaceuticals, Inc. today reported recent achievements and financial results for the third quarter ended September 30, 2017.. “We are thrilled that GOCOVRI ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.